NCT04359550View on ClinicalTrials.gov

Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy

PHASE3UnknownINTERVENTIONAL
Enrollment

362

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

June 1, 2022

Study Completion Date

June 1, 2023

Conditions
High-grade Osteosarcoma
Interventions
BIOLOGICAL

Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)

Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)

OTHER

placebo

placebo

Sponsors
All Listed Sponsors
lead

Lee's Pharmaceutical Limited

INDUSTRY